Neonatal hypotonia and neuromuscular weakness

Overview & Definition

Picture the infant first: a floppy, frog-legged neonate who slips through the examiner's hands, with head lag on pull-to-sit, a scarf sign that brings the elbow across the midline, and reduced resistance to passive movement. That is hypotonia — a decrease in postural muscle tone. It is not the same as weakness, which is a loss of active force, and the distinction matters because a hypotonic infant is not always weak. The decisive bedside question is therefore not "is this baby floppy?" but "is this baby also weak?" — and that single observation reorders the whole differential. ^[10]

Neonatal hypotonia is the presenting feature of a long list of disorders, and the first act is to split the list into two. Central hypotonia (a problem of the brain, roughly 80% of presentations) preserves strength and reflexes because the motor unit below it is intact. Peripheral hypotonia (a problem of the motor unit — anterior horn cell, nerve, neuromuscular junction or muscle, roughly 20%) lowers tone together with strength and reflexes, because the machinery that generates force is itself failing. Spinal muscular atrophy is the commonest inherited peripheral cause, congenital myotonic dystrophy the commonest congenital muscular dystrophy seen in the neonate, and Prader-Willi syndrome a frequent central cause. ^{[10] [4]}

The split is decisive because the peripheral cohort holds the treatable, time-critical disease. Spinal muscular atrophy, untreated, kills motor neurons irreversibly and ends in fatal respiratory failure in infancy; treated before symptoms with nusinersen or gene therapy, the same infant can sit, stand and survive. So the floppy neonate is a neurology emergency, not a "wait and see" presentation. ^{[1] [2]}

References10ShowHide

1. [1]Finkel RS; Mercuri E; Darras BT; Connolly AM; et al Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy. N Engl J Med, 2017.PMID 29091570
2. [2]Strauss KA; Farrar MA; Muntoni F; Saito K; et al Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial. Nat Med, 2022.PMID 35715567
3. [3]Mercuri E; Finkel RS; Muntoni F; Wirth B; et al Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord, 2018.PMID 29290580
4. [4]Verhaart IEC; Robertson A; Wilson IJ; Aartsma-Rus A; et al Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review. Orphanet J Rare Dis, 2017.PMID 28676062
5. [5]Glascock J; Sampson J; Haidet-Phillips A; Connolly A; et al Treatment Algorithm for Infants Diagnosed with Spinal Muscular Atrophy through Newborn Screening. J Neuromuscul Dis, 2018.PMID 29614695
6. [6]Cassidy SB; Schwartz S; Miller JL; Driscoll DJ Prader-Willi syndrome. Genet Med, 2012.PMID 22237428
7. [7]Singh P; Mahmoud R; Gold JA; Miller JL; et al Multicentre study of maternal and neonatal outcomes in individuals with Prader-Willi syndrome. J Med Genet, 2018.PMID 29776967
8. [8]Jungbluth H; Sewry CA; Muntoni F What's new in neuromuscular disorders? The congenital myopathies. Eur J Paediatr Neurol, 2003.PMID 12615171
9. [9]Ostojić S; Kovačević G; Meola G; Pešović J; et al Main features and disease outcome of congenital myotonic dystrophy - experience from a single tertiary center. Neuromuscul Disord, 2024.PMID 38810326
10. [10]Bodensteiner JB The evaluation of the hypotonic infant. Semin Pediatr Neurol, 2008.PMID 18342256